Revolutionising immunotherapy and anti-infectives for the most vulnerable patients

Driven by science

Our Alphamer® technology offers a unique approach to immunotherapy. By harnessing naturally-occurring and ubiquitous anti-glycan antibodies to engage the host immune system and redirect it towards disease targets, Alphamers enable us to combat infection in even the most vulnerable patients.

Harnessing the host response

At Centauri, we believe that successful treatment of infection requires addressing both the pathogen and the host. Our Alphamer® technology is designed to overcome existing failures in treatment by combining direct antibacterial activity with a targeted and clinically-validated immune mechanism.

Alphamers® are powerful and versatile immunotherapeutics with the potential to transform treatment options for high-risk patients across life-threatening indications. Initially focused on infectious disease, our pipeline includes our lead clinical candidate CTX-187 – a novel immunotherapy for the treatment of Gram-negative bacterial infections.